One study found that, on a per-cell basis, in vitro-generated tumor-specific TCM-like CD8+ T cells were able to mount a strong recall response to tumors greater than that of their TEM-like cultured counterparts and were capable of eradicating established tumors when combined with both exogenous IL-2 and a cancer-antigen vaccination strategy (170). This evidence concerns the gene CD8A and neoplasm.